{name}
{subtitle}
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~11 mi. (Lárisa, Greece, +93 more cities)
facility
University General Hospital of Larissa ( Site 0302)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~11 mi. (Lárisa, Greece, +130 more cities)
facility
University Hospital of Larissa ( Site 0301)
drug
BCG solution, +1 more drug
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~41 mi. (Yeraklíon, Greece, +192 more cities)
facility
University General Hospital of Heraklion
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~41 mi. (Yeraklíon, Greece, +122 more cities)
facility
University General Hospital of Herakleion ( Site 1202)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~41 mi. (Yeraklíon, Greece, +197 more cities)
facility
University General Hospital of Heraklion PA.G.N.I /ID# 214075
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~41 mi. (Yeraklíon, Greece, +156 more cities)
facility
University General Hospital of Heraklion PA.G.N.I /ID# 222879
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type